Companies are now expected to have their tests cleared by authorities for clinical use, and to bring their entire catalogs into line with the new regulations by May 2022.
The company said it will use the funds to expand its menu of STI tests and launch its io rapid diagnostic platform into UK sexual health clinics.
The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.
Researches are advancing it mainly for use in mosquito surveillance efforts, but also collected data supporting clinical testing of human samples.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The firm is considering separating the point-of-care and lab test arms of its business, delisting its shares, and buying back stock from shareholders.
The funding comes from a syndicate which includes all Series C investors and one new investor, Chinese assay developer Wondfo Biotech.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.
Singapore Eye Research Institute's Roger Beuerman wants to bring point-of-care eye diagnostics to the ophthalmologist's office.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.
Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.
Researchers link genetic links between education and smoking and longevity.
In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.